CoLucid owns or has exclusive rights to a significant worldwide patent portfolio covering both the 5-HT1F Receptor Agonists and the Conjugated Stigmines. Please see the attached list for a representative sampling of published applications and issued patents in the CoLucid portfolio.
| 5-HT1F Receptor Agonists | ||
|---|---|---|
| U.S. Patent No. 7,423,050 | "Pyridinoylpiperidines as 5-HT1F Agonists" | Download |
| WO 2010/115125 | "Composition of 2,4,6-Trifluoro-N-[6-(-1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide" | Download |
| Conjugated Stigmines | ||
| U.S. Patent No. 7,897,639 | "Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents" | Download |
| U.S. Patent No. 7,795,307 | "Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents" | Download |
| WO 2008/097546 | "Compounds that inhibit cholinesterase" | Download |
| WO 2009/011901 | "Methods for promoting wakefulness" | Download |
| WO 2010/009316 | "Stigmine Conjugates for Substance Abuse Disorders" | Download |
| WO 2010/115124 | "Compositions of Cholinesterase Inhibitors" | Download |
